Cargando…
Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients
Microsatellite instability (MSI) testing identifies patients who may benefit from immune checkpoint inhibitors. We developed an MSI assay that uses data from a commercially available next‐generation sequencing (NGS) panel to determine MSI status. The assay is applicable across cancer types and does...
Autores principales: | Vanderwalde, Ari, Spetzler, David, Xiao, Nianqing, Gatalica, Zoran, Marshall, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852359/ https://www.ncbi.nlm.nih.gov/pubmed/29436178 http://dx.doi.org/10.1002/cam4.1372 |
Ejemplares similares
-
Population bias in somatic measurement of microsatellite instability status
por: Saul, Michelle, et al.
Publicado: (2020) -
Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patients
por: Nikanjam, Mina, et al.
Publicado: (2019) -
High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine
por: Gatalica, Zoran, et al.
Publicado: (2016) -
High Lymph Node Yield is Related to Microsatellite Instability in Colon Cancer
por: Belt, E. J. Th., et al.
Publicado: (2011) -
Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma
por: Qiu, Miao‐Zhen, et al.
Publicado: (2021)